News

This study confirmed reports from the CDC and Israel Ministry of Health that found the Pfizer-BioNTech vaccine waned after 6 months.

A study found similar rates of acute respiratory illness-related visits across race/ethnicity when all healthcare settings were combined, but ARI visits differed for race/ethnicity groups across ambulatory, emergency, and hospital settings.

Learn more about new test for diagnosing early Lyme disease in a Q&A with Adaptive Biotechnologies.

Self-testing for HIV is fast and easy, and test kits can be completed at a health department with the help of staff or at home and dropped off later.

If the company gets approval it would be the first dispersible single tablet regimen containing dolutegravir.

As more agents expand the capability and variety of PrEP options, investigators consider what questions remain about the drug class.

Following the approval of cabotegravir-rilpivirine earlier this year, experts are looking forward to an expansion of the drug class for HIV.

The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

The findings have supported the launch of a phase 3 trial called EVERGREEN, which is now underway.

A conversation in consideration of the high-risk psychosocial comorbidities the aging HIV population may face through COVID-19.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.

The COVID-19 pandemic led people to take hygiene and sanitation more seriously, causing a decrease in C difficile infections.

A clinician provides an overview of the data on the microbiota-based live biotherapeutic, RBX2660, which in phase 3 studies has shown safety and reduction in recurrent C difficile infection (rCDI).

After an initial hospitalization for COVID-19, some patients may have specific risk factors that increase their likelihood of readmittance.

Investigators wanted to understand this phenomenon with a group of antiretroviral (ART) naïve people with HIV (PWH).

Massachusetts General Hospital investigated how international travel contributes to the contraction and carriage of antimicrobial resistance (AMR).

Major predictors of response were CD4+ count, suppressed viral load, and whether the participant received the Moderna or Pfizer mRNA vaccine.

The Arkansas Health Department’s research showed that, as with the rest of the population, Delta is severely infectious for children.

Investigators examined asymptomatic infection and the duration of viral shedding in symptomatic breakthrough infections in a phase 3 study with the AZD1222 COVID-19 vaccine.

Unpublished, interim phase 3 data show an approximate 50% reduction in hospitalizations and deaths versus placebo. Merck is expediting FDA application for the antiviral drug.

This type of stewardship is a means of reducing unnecessary testing, getting the appropriate diagnosis more efficiently, and getting patients the appropriate therapy in a timely manner.

In the primary efficacy analysis, the risk of developing symptomatic COVID 19 was reduced by 77% with AZD7442.

The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.

A survey found most healthcare professionals would clear an asymptomatic patient with a positive PCR test if the patient met other criteria.

In a study looking at one urban South Florida hospital, the pandemic negatively impacted testing.

A study found disproportionately higher COVID-19 cases in Black and Hispanic people with HIV across the US.

A study’s findings support the use of the therapy earlier in the course of COVID-19 in hospitalized patients.